A Phase 3 interventional study of Liberal RBC Transfusion and Restrictive RBC Transfusion in Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome) and Intensive Care Medicine, sponsored by Australian and New Zealand Intensive Care Research Centre. Recruiting at 3 sites in Australia. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Australian and New Zealand Intensive Care Research Centre · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO)
The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO.
Researchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort.
Participants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.
The RECOMMEND Platform trial is an investigator initiated, multicentre, open labelled, randomised controlled Platform Trial that will utilise Bayesian adaptive logic to investigate the efficacy and safety of multiple study interventions simultaneously or sequentially in cohorts of adult patients who are receiving ECMO from ICUs participating in the national ECMO registry (EXCEL) in Australian hospitals (EXCEL Registry NCT03793257).
In this platform trial, various interventions will be investigated for their potential to improve outcomes for patients undergoing ECMO.
Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intensive treatment used to support critically ill patients suffering from severe cardiac arrest, cardiac failure or respiratory failure. ECMO provides mechanical circulatory support, temporarily replacing the function of the heart and/or lungs, allowing time for these organs to recover.
Globally, the use of ECMO has increased rapidly over the past decade. It is both invasive and expensive, with the average cost for a single admission in Australia exceeding more than $180,000 and a total annual cost of > $75 million. Despite its high cost, ECMO is associated with a high mortality rate, and many survivors have compromised functional recovery for months or years after discharge from hospital, further adding to the long-terms costs of care.
The main complications reported in the national ECMO registry from 2019-2022 include bleeding (51.4%), renal failure and fluid overload (78.4%), and death and ongoing disability (66%). These were confirmed as research priorities by consumers and end-users. While the use of ECMO increases swiftly, the evidence base to support the growing patient numbers receiving this care has not grown at the same rate, resulting in important evidence gaps.
The RECOMMEND Platform Trial will address these evidence gaps in ECMO services in Australia. A platform trial is a type of study design that evaluates multiple treatment interventions for a single condition or device simultaneously within a single, overarching framework. This framework operates similarly to a standard operating procedure for study logistics, ethics management, funding, staffing, and statistical and data collection methods. Having an approved process (platform) for the 'Platform Trial' to operate saves time and money and increases speed of clinical trial onboarding to outcome resolution for researchers, hospital staff, ethics committees, and stakeholders. With this platform in place, future studies of similar ECMO outcomes can be onboarded more efficiently, as described above, and it creates a more powerful pool of data for impactful patient-centred research.
Over the lifetime of RECOMMEND, it is anticipated that new interventions will be added as new domains. The creation of new domains will be considered according to priorities set by relevant working groups, based on existing or new clinical need and there being sufficient statistical power available within RECOMMEND.
382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.
This study's planned enrollment of 600 is above the median of 60 across 227 interventional studies indexed under Acute Lung Injury.
Browse Acute Lung Injury studies →Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
PLATFORM INCLUSION CRITERIA:
PLATFORM EXCLUSION CRITERIA:
RBC TRANSFUSION DOMAIN INCLUSION CRITERIA:
RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RBC Transfusion Domain: Patients on ECMO in ICU enrolled in the RBC Transfusion Domain of RECOMMEND. Patients receive one of two RBC transfusion strategies (restrictive or liberal)
Other: Liberal RBC Transfusion · Other: Restrictive RBC Transfusion
Liberal transfusion trigger group (patient receives RBC transfusion if Hb \<90g/L).
Restrictive transfusion trigger group (patient receives RBC transfusion if Hb \<70g/L).
Daily Organ Support for patients on ECMO (DOSE-score).
The primary outcome is the Daily Organ Support for patients on ECMO (DOSE-score), a 6-level daily ordinal outcome measured as the worst status of a patient on each day from day 1 through to day 28 inclusive, which reflects survival, organ support and resource utilisation: 1. dead; 2. on ECMO; 3. invasively mechanically ventilated without ECMO; 4. in ICU but not invasively mechanically ventilated nor on ECMO; 5. in hospital; and 6. discharged from the hospital alive.
Time frame: 28-days.
Development of major haemorrhage at 28 days
Development of major haemorrhage
Time frame: 28-days.
Development of intracranial haemorrhage at 28 days
Development of intracranial haemorrhage
Time frame: 28 days
Mortality at 28 days
Living status.
Time frame: 28 days
ECMO-free days at 28 days
Number of days not receiving ECMO
Time frame: 28 days
Ventilator-free days at 28 days
Number of days not receiving ventilation
Time frame: 28 days
Mortality at 180 days
Platform Trial Tertiary Outcome
Time frame: 180 days
Disability at 180 days
Platform Trial Tertiary Outcome - measured by WHODAS 2.0 at 180-days
Time frame: 180 days
Functional Status at 180 days
Platform Trial Tertiary Outcome - measured using Lawton-Brody IADL and Barthel ADL
Time frame: 180 days
Quality of Life at 180 days
Platform Trial Tertiary Outcome - measured by Eq-5D-5L and EQ-VAS
Time frame: 180 days
ICU Length of Stay
Platform Trial Tertiary Outcome
Time frame: 180 days
Hospital Length of Stay
Platform Trial Tertiary Outcome - separated for survivors and non-survivors
Time frame: 180 days
Number and Nature of SAEs
RBC Transfusion Domain Specific Outcome
Time frame: 28 days
Mortality in ICU
RBC Transfusion Domain Specific Outcome
Time frame: 180 days
Total Blood Products
RBC Transfusion Domain Specific Outcome - administered until cessation of ECMO or 28 days, whichever occurs first
Time frame: 28 days
Total RBC Units
RBC Transfusion Domain Specific Outcome - administered until cessation of ECMO or 28 days, whichever occurs first
Time frame: 28 days
Plan to share: No — No IPD is created as individual data are not shared. However, aggregated data presented in manuscripts and publications or similar works, will be accessible upon patient request or own investigation.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2028, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australian and New Zealand Intensive Care Research Centre